Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis
暂无分享,去创建一个
[1] V. Chiesa,et al. Unravelling the Process from Closed to Open Innovation: Evidence from Mature, Asset-Intensive Industries , 2010 .
[2] Daniel Tolstoy,et al. Network resource combinations in the international venturing of small biotech firms , 2010 .
[3] Yu-An Huang,et al. R&D sourcing strategies: Determinants and consequences , 2009 .
[4] Soumodip Sarkar,et al. Dynamics of open innovation in the food industry , 2008 .
[5] Stephen Roper,et al. From capability to connectivity — absorptive capacity and exploratory alliances in biopharmaceutical firms: a US–Europe comparison , 2008 .
[6] R. Smits,et al. The role of users in innovation in the pharmaceutical industry. , 2008, Drug discovery today.
[7] Davide Chiaroni,et al. The knowledge-bridging role of Technical and Scientific Services in knowledge-intensive industries , 2008, Int. J. Technol. Manag..
[8] J. West,et al. Open innovation : researching a new paradigm , 2008 .
[9] M. Perkmann,et al. University Industry Relationships and Open Innovation: Towards a Research Agenda , 2007 .
[10] G. Duysters,et al. Networking as a Means to Strategy Change: The Case of Open Innovation in Mobile Telephony , 2007 .
[11] Han van der Meer,et al. Open Innovation – The Dutch Treat: Challenges in Thinking in Business Models , 2007 .
[12] K. Reardon. Courage as a skill. , 2007, Harvard business review.
[13] Bernard H. Munos,et al. Can open-source R&D reinvigorate drug research? , 2006, Nature Reviews Drug Discovery.
[14] Cornelia Dröge,et al. Collaborating for new product development: Selecting the partner with maximum potential to create value , 2006 .
[15] W. Vanhaverbeke,et al. Choosing Governance Modes for External Technology Sourcing , 2006 .
[16] H. Chesbrough,et al. Beyond High Tech: Early Adopters of Open Innovation in Other Industries , 2006 .
[17] Oliver Gassmann,et al. Opening Up the Innovation Process: Towards an Agenda , 2006 .
[18] Dirk Voelkel,et al. Managing Open Innovation in Biotechnology , 2006 .
[19] Roland Ortt,et al. Innovation management: different approaches to cope with the same trends , 2006, Int. J. Technol. Manag..
[20] A. Salter,et al. Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms , 2006 .
[21] N. Sakkab,et al. Connect and Develop : Inside Procter & Gamble's New Model for Innovation , 2006 .
[22] Henry Chesbrough,et al. Open Innovation: A research agenda , 2006 .
[23] Jens Frøslev Christensen,et al. The industrial dynamics of Open Innovation—Evidence from the transformation of consumer electronics , 2005 .
[24] Ulrich Lichtenthaler,et al. External Commercialization of Knowledge: Review and Research Agenda , 2005 .
[25] Oliver Gassmann,et al. Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .
[26] Robert Kirschbaum,et al. Open Innovation In Practice , 2005 .
[27] Nader A. Salman,et al. Indirect Networks: An Intangible Resource for Biotechnology Innovation , 2005 .
[28] Davide Chiaroni,et al. Industrial Clusters In Biotechnology , 2004 .
[29] Zi-Lin He,et al. Exploration vs. Exploitation: An Empirical Test of the Ambidexterity Hypothesis , 2004, Organ. Sci..
[30] Eckhard Lichtenthaler,et al. Organising the external technology exploitation process: current practices and future challenges , 2004, Int. J. Technol. Manag..
[31] Ove Granstrand,et al. The economics and management of technology trade: towards a pro-licensing era? , 2004, Int. J. Technol. Manag..
[32] Georges Haour. Resolving the Innovation Paradox , 2004 .
[33] Georges Haour,et al. Resolving the Innovation Paradox: Enhancing Growth in Technology Companies , 2003 .
[34] J. Niosi. Alliances are not enough explaining rapid growth in biotechnology firms , 2003 .
[35] Henry Chesbrough,et al. Open Innovation: The New Imperative for Creating and Profiting from Technology , 2003 .
[36] V. Chiesa,et al. La bioindustria - strategie competitive e organizzazione industriale nel settore delle biotecnologie farmaceutiche , 2003 .
[37] Giuseppe Giardina,et al. INNOVAZIONI NEI PROCESSI DI RICERCA IN CAMPO FARMACEUTICO , 2003 .
[38] Hildy Teegen,et al. Factors affecting foreign R&D location decisions: management and host policy implications , 2003, Int. J. Technol. Manag..
[39] Kenneth W. Koput,et al. The Spatial Clustering of Science and Capital: Accounting for Biotech Firm-Venture Capital Relationships , 2002 .
[40] Walter W. Powell,et al. A Comparison of U.S. and European University-Industry Relations in the Life Sciences , 2001 .
[41] E. Roberts. Benchmarking Global Strategic Management of Technology , 2001 .
[42] Vittorio Chiesa,et al. R&D Strategy and Organisation:Managing Technical Change in Dynamic Contexts , 2001 .
[43] Anoop Madhok,et al. The International Biotechnology Industry: A Dynamic Capabilities Perspective , 2000 .
[44] Joel A. C. Baum,et al. Don't go it alone: alliance network composition and startups' performance in Canadian biotechnology , 2000 .
[45] David L. Deeds,et al. The impact of stocks and flows of organizational knowledge on firm performance: an empirical investigation of the biotechnology industry , 1999 .
[46] David Wilemon,et al. Changing patterns in industrial R&D management , 1996 .
[47] Deb Chatterji,et al. Accessing External Sources of Technology , 1996 .
[48] W. Powell,et al. Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .
[49] J. Davidson,et al. Quality deployment in R&D organizations , 1996 .
[50] Barry L. Bayus,et al. Are Product Life Cycles Really Getting Shorter , 1994 .
[51] J. March. Exploration and exploitation in organizational learning , 1991, STUDI ORGANIZZATIVI.
[52] A. Pettigrew. Longitudinal Field Research on Change: Theory and Practice , 1990 .
[53] Mark S. Granovetter. The Strength of Weak Ties , 1973, American Journal of Sociology.